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Background: There has been a growing emphasis on evidence-informed decision-making in health care. Systematic
reviews, such as those produced by the Cochrane Collaboration, have been a key component of this movement. The
UK National Institute for Health Research (NIHR) Systematic Review Programme currently supports 20 Cochrane Review
Groups (CRGs). The aim of this study was to identify the impacts of Cochrane reviews published by NIHR-funded CRGs
during the years 2007–2011.
Methods: We sent questionnaires to CRGs and review authors, interviewed guideline developers and used bibliometrics
and documentary review to get an overview of CRG impact and to evaluate the impact of a sample of 60 Cochrane
reviews. We used a framework with four categories (knowledge production, research targeting, informing policy
development and impact on practice/services).
Results: A total of 1,502 new and updated reviews were produced by the 20 NIHR-funded CRGs between 2007 and
2011. The clearest impacts were on policy with a total of 483 systematic reviews cited in 247 sets of guidance: 62 were
international, 175 national (87 from the UK) and 10 local. Review authors and CRGs provided some examples of impact
on practice or services, for example, safer use of medication, the identification of new effective drugs or treatments and
potential economic benefits through the reduction in the use of unproven or unnecessary procedures. However, such
impacts are difficult to objectively document, and the majority of reviewers were unsure if their review had produced
specific impacts. Qualitative data suggested that Cochrane reviews often play an instrumental role in informing guidance,
although a poor fit with guideline scope or methods, reviews being out of date and a lack of communication between
CRGs and guideline developers were barriers to their use.
Conclusions: Health and economic impacts of research are generally difficult to measure. We found that to be the case
with this evaluation. Impacts on knowledge production and clinical guidance were easier to identify and substantiate
than those on clinical practice. Questions remain about how we define and measure impact, and more work is needed
to develop suitable methods for impact analysis.
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In recent years, there has been a growing emphasis on the
use of evidence to inform decision-making in health care
[1-3], with the use of evidence seen as particularly relevant
to commissioning because of the large financial commit-
ments involved and because of the increasing complexity
of health-care management decisions [4]. In addition, there
has been growing interest in the way in which research
is used, with researchers increasingly expected to consider
the wider impacts of their work [5]. This may include the
contributions research makes to health, society, culture,
the economy, quality of life and public policy.
One of the key aspects of evidence-informed policy and
practice has been the development of methods for the
synthesis and integration of primary research, in the
form of systematic reviews. Systematic reviews have
been regarded as particularly important tools for
decision-makers as it inherently makes sense for deci-
sions to be based on the totality of evidence rather
than a single study [6,7]. However, despite this, the
extent to which policy makers and practitioners use
systematic reviews as a source of evidence has been
questioned [4,6]. Indeed, it has long been recognised
that research may not always have the impact that re-
searchers desire [8,9].
The Cochrane Collaboration is an independent, inter-
national organisation involved in preparing, maintaining
and disseminating systematic reviews evaluating the effect-
iveness of health-care interventions. Cochrane systematic
reviews should be uniquely placed to influence policy,
practice and research as they provide a comprehensive,
critical summary of what is known about effectiveness on
a given topic; the rigour of their methods is widely
acknowledged, and they are periodically updated in light
of new evidence. However, whilst it is acknowledged
that Cochrane groups produce high-quality systematic
reviews [10-12], there is at present a lack of informa-
tion about the impacts of Cochrane reviews.
The UK National Institute for Health Research
(NIHR) systematic review programme currently supports
20 Cochrane Review Groups (CRGs) that have their edi-
torial bases in academic or health institutions in the UK.
These groups cover a broad range of health-care
areas and produce almost half of all Cochrane re-
views. This study was commissioned by the NIHR to
identify the impacts and likely impacts of Cochrane
reviews published by the 20 NIHR-funded CRGs between
the years 2007 and 2011. The aims of this study were to
identify impacts on clinical guidance and clinical
practice and identify important gaps in knowledge
and possible influence on the conduct of new primary
research studies. In addition, we sought to identify barriers
and facilitators to Cochrane reviews being used by guideline
developers.Methods
We used a mixed methods approach informed by theories
about research impact [9,13-15] and guided by a
framework that draws on previous work around the
evaluation of research impact [16-19]. This frame-
work, including main and subcategories, can be seen
in Table 1. A variety of methods exist for evaluating
research impact including bibliometrics, documentary
analysis, semi-structured interviews, case studies and
surveys [20,21]. As there are advantages and disad-
vantages of each method, it is generally recommended
that a variety of sources to identify research impact
are used [22,23]. We used a mixture of bibliometrics,
documentary analysis, questionnaire surveys and inter-
views. Obtaining the ‘insider account’ has been recom-
mended when evaluating research impact [21], and it was
envisaged that staff at editorial bases and review authors
would be important sources of information about review
impact.
There were two main components to the study. In
the first (phase 1), we aimed to obtain a general
overview of the impact of the outputs produced by
NIHR-funded CRGs, and in the second (phase 2), we
undertook a more detailed evaluation of a sample of
Cochrane reviews. The study was conducted between
April and September 2013 and only included reviews
first published or updated during the years 2007–2011
(time period was stipulated by the funder). The eva-
luation covered the following CRGs: Airways; Bone,
Joint and Muscle Trauma; Cystic Fibrosis and Genetic
Disorders Group; Dementia and Cognitive Improvement;
Depression, Anxiety and Neurosis; Ear, Nose and Throat;
Epilepsy; Eyes and Vision; Gynaecological Cancer; Heart;
Incontinence; Injuries; Neuromuscular; Oral Health; Pain,
Palliative and Supportive Care; Pregnancy and Childbirth;
Schizophrenia; Skin; Tobacco Addiction; and Wounds.
For an overview of study methods, including how
each part informs the findings, see Figure 1.
Ethical approval for the study was obtained from the
University of Hertfordshire Health and Human Sciences
Ethics Committee with delegated authority (ECDA), ref-
erence number HSK/SF/UH/00003.
Methods for phase 1: overview of impact of CRG outputs
(2007–2011)
Questionnaire survey
We sent a questionnaire survey (Additional file 1) to the
editorial base (n = 20) of each NIHR-funded CRG. The
questionnaires were sent via email with a personalised cov-
ering letter explaining the purpose of the study. The survey
included questions about general impact (both actual and
potential) of the CRG output between the years 2007 and
2011; the questions were informed by our evaluation
framework. Respondents were asked, where possible, to
Table 1 Evaluation framework
Main category Subcategories Further details
1. Knowledge production • Impact within research community • Number of times review is cited
• Stimulating debate in research community
• Methodological developments
• Other methods of dissemination • Press coverage
2. Research targeting • Influence on other research • Identification of gaps in knowledge
• Follow-on research
3. Informing policy development
(includes actual and potential)
• Impact on national or government policy • e.g. NICE guidance
• Impact on international policy • e.g. WHO guidance, or international
professional bodies
• Policies agreed at national or local level in the
form of clinical or local guidelines
• e.g. Guidance produced by local trusts
• Policies developed by those responsible for
training and education
• Local or national
4. Impact on practice/services
(includes actual and potential)
• Evidence-based practice • The use of research evidence by different groups
involved in clinical decision-making
• Adoption of research findings and health
technologies by health-service providers
• Adherence to research-informed policies and
guidelines
• Addressing barriers to evidence-based practice
(e.g. training)
• Number of mentions in media
• Quality of care • Efficacy of health services
• Availability, accessibility and acceptability of services
• Utilisation and coverage
• Cost containment and cost-effectiveness
• Services management and organisation • Management of health-service procurement and
provisioning (public and private)
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citation in clinical guidelines, impact on practice (for
example, changes to clinicians behaviour, changes to service
organisation and delivery), or influence on future primary
research. CRGs were also asked to identify reviews pub-
lished (or updated) in the last 5 years that they considered
to have had the most impact on policy and practice.
Documentary review and analysis of existing sources
In addition to the questionnaires, we hand-searched the
annual reports that CRGs had provided to the NIHR
Health Technology Assessment (HTA) programme for the
years 2007–2012, reviewed data on the use of Cochrane
reviews in National Institute for Health and Care Excel-
lence (NICE) and Scottish Intercollegiate Guidelines
Network (SIGN) guidance compiled by the UK Cochrane
Centre and searched the Cochrane Quality, Innovation,
Productivity and Prevention (QIPP) topics database via
NHS Evidence (https://www.evidence.nhs.uk/qipp). This
documentary analysis was supplemented with keyword
searches on a number of databases and internet sitesincluding Google, NHS Evidence, and the World Health
Organisation (WHO).
Data verification and analysis
Data from the questionnaires were entered on an Excel
spreadsheet. One researcher extracted examples of actual
or potential impact for each CRG and recorded this on a
specially designed data extraction form based on the
categories from our framework (Additional file 2).
Additional data identified via documentary review was
added to this form. Data relating to guidelines were
collated in a separate Excel spreadsheet which was
stratified by CRG. Data, and how to interpret it, was
discussed with a second member of the team. Infor-
mation was critically assessed and, where possible, evi-
dence sought to verify it. For example, when a review
was said to have led to follow-on research, we searched
for the study protocol or final report in order to check
that the review had been cited as justification for the
research, and we obtained hard copies of guidelines
and searched using the word ‘Cochrane’ to verify which
Figure 1 Overview of methods.
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the time frame for this evaluation (2007–2011). We ex-
cluded examples where no supporting evidence was
available.
Qualitative interviews
We undertook telephone interviews with a convenience
sample of guideline developers; this included those in-
volved in developing and managing guidelines and system-
atic reviewers and technical advisors producing evidence
reviews to underpin guidance. In the UK, participants were
recruited from NICE (or one of their collaborating centres)
or SIGN, and international participants were recruited via
the WHO.
Potential participants were identified by one of the
authors with further snowballing as required. Our ap-
proach was iterative, and recruitment was stopped when
we felt that we had reached data saturation. We used a
semi-structured interview schedule which included ques-
tions about how systematic reviews were used in the de-
velopment of guidance, experiences of using Cochrane
reviews and ways in which use of Cochrane reviews might
be facilitated. Interviews lasted between 20 and 40 min
and were taped and transcribed. Informed consent was
obtained from each participant.
Analysis
We drew on thematic content analysis to enable key
features of guideline developers’ experiences of using
Cochrane reviews to be elicited from the data [24]. To guar-
antee a degree of inter-rater reliability and transparency,two researchers independently scrutinised each transcript
and applied open codes to text. From this, a list of initial
codes and themes were created. This was refined after fur-
ther discussion with the wider project team, and support-
ing evidence in the form of quotes was documented.
Methods for phase 2: evaluation of impact of
representative sample of Cochrane reviews (2007–2011)
In phase 2, we undertook further analysis on a purposive
sample of 60 Cochrane reviews published or updated bet-
ween 2007 and 2011. For each CRG, we chose one review
randomly and two on the basis that they had potentially
had an impact. Where possible, we used the information
provided by CRGs in their questionnaires to inform the se-
lection of reviews. However, in some cases, CRGs did not
provide this information and we used other sources, such
as citation counts or data from Wiley (publishers of the
Cochrane Library), to guide our selection. As impact may
take some time to build, we weighted our sample towards
those reviews published between the years 2007 and 2010.
Questionnaire survey with systematic review authors
We sent a questionnaire survey (Additional file 3) to first
authors of all 60 reviews. Questions were similar to those in
the CRG questionnaire with authors asked to consider im-
pact on knowledge production and possible impact of the
review on health policy and practice. Authors were also
asked if they thought their review identified important gaps
in knowledge and/or if it had any influence on the conduct
of new primary research. Methods for analysis and data
verification were similar to those for the CRG questionnaire.
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searchers and, in addition, 26 authors were followed up by
the Managing Editors at CRG editorial bases.
Documentary and bibliometric analysis
We undertook citation analysis in Web of Science
(WoS), Scopus and Google Scholar (searches conducted
May/June 2013); undertook searches on Google, NHS
Evidence and TRIP ( http://www.tripdatabase.com/) using
review author and title keywords (between May and July
2013); and reviewed data from the publishers of The
Cochrane Library (Wiley) on review downloads and media
mentions. We also used an alternative metric measure
(http://www.altmetric.com/). This provides article level
metrics which give an indication of the impact of a
publication by looking at activity surrounding the
publication on social media sites and in policy documents
and newspapers. Articles for which no mentions have been
recorded score 0. Results from the documentary and
bibliometric analyses were entered into a specially designed
data extraction form in Access (see Additional file 4). Data
on citation counts was entered by one researcher and
checked by a second.
Results
A total of 3,187 new and updated reviews were published
on the Cochrane Database of Systematic Reviews between
2007 and 2011, 1,502 (47%) of which were produced by
the 20 CRGs funded by the NIHR (see Figure 2).
Seventeen of the 20 (85%) CRGs and 29 (48%) of review
authors returned questionnaires. There was some vari-
ation in the number of author questionnaires returned for
each CRG with all three questionnaires returned for some
groups and none for others. Of the 60 reviews selected for
analysis, 9 (15%) were updates and the rest were new
reviews. Thirteen (22%) were published in 2007, 23 (38%)Figure 2 New and updated reviews published between 2007 and 201in 2008, 12 (20%) in 2009 and 6 (10%) in 2010 and 2011,
respectively. Thirty-four (57%) of the first authors
were based in the UK. Details of these reviews, in-
cluding title, country of first author and whether they
were a new review or an updated review, can be seen
in Additional file 5.
Knowledge production, identifying gaps in the evidence
and stimulating research
CRG and author questionnaires provided 40 examples
where they felt reviews had influenced primary research,
and 13 (22%) of the sample of 60 reviews had been cited
in a protocol or the background of a primary research
study. In general, most of these examples related to
work conducted by the Cochrane reviewers themselves;
respondents to the questionnaires were less sure if their
review had influenced the research of others. Most of the
examples of follow-on research were RCTs. A summary
by CRG can be seen in Table 2.
Although there was considerable variation between the
reviews, the data do suggest that many of the 60 reviews
have been of interest to decision makers. For example,
27 (45%) of the 60 reviews had had 100 or more citations
in Google Scholar and 5 had received over 400 citations.
Citation counts were higher in Google Scholar than in
WoS or Scopus. The number of downloads from the
Cochrane Library varied considerably between reviews. Of
the sample of 60 reviews, the ten that were downloaded
most frequently (full text and abstract) for the years
2009–2011 can be seen in Figure 3. This figure give an
indication of the impact of reviews within the research
and practice communities and show how downloads for
reviews have increased over the 5-year period.
Thirty-six (60%) of the 60 reviews had an Altmetric
score of 1 or more with 12 (20%) having a score over 10,
and 4 (7%) scoring over 50. Currently, mid-tier publications1 (stratified by CRG).
Table 2 Number of reviews informing primary research
CRG Number of
reviews
Type and number
follow-on research
Review is citeda Type of funder
Airways 1 RCT Yes Not known
Bones, Joint and Muscle 2 2 RCTs Yes Government (1 UK, 1 Australia)
Cystic Fibrosis 5 5 RCTs Yes 3 government (UK), 2 not known
Depression, Anxiety and Neurosis 2 1 RCT, 1 not known 1 Yes, 1 not known 1 government (UK), 1 not known
Eyes and Vision 1 1 Not known Yes 1 charity
Incontinence 3 3 RCTs 2 Yes, 1 not known 3 government (UK)
Injuries 7 9 RCTs 7 Yes, 2 not known 7 government (3 Australia, 3 UK, 1 Denmark),
1 industry, 1 charity
Neuromuscular 4 3 RCTs, 1 not known 2 Yes, 2 not known 2 government (1 USA, 1 France), 1 charity,
1 not known
Oral 1 RCT Yes 1 government (UK)
Pregnancy 1 Qualitative Yes Not known
Schizophrenia 1 1 RCT, 2 not known Not known Not known
Skin 5 5 RCTs, 1 not known 4 Yes, 2 not known 3 government (UK), 2 charity (2 UK, 1 USA)
Tobacco Addiction 2 3 RCTs Yes (all) 2 government (UK), 1 not known
aThis relates to whether we found a study protocol or publication that cited the original Cochrane review.
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1 [25]. Although these scores need to be interpreted cau-
tiously, for example, they may not accurately reflect the
interest in reviews published before 2011, they do provide
some indication of the interest around a review and the
way Cochrane reviews may have impacted on knowledge
production by stimulating discussion and debate [26].
Citations counts and Altmetric scores for each review can
be seen in Table 3 with a summary of citation analysis data
in Table 4.
Informing policy development
Systematic reviews from all the 20 CRGs were cited
in some form of clinical or practice guidance. Across
the CRGs, there were 722 citations in 248 guidelines
(or in the evidence reviews used to develop the guid-
ance) with 481 systematic reviews being cited at least
once. Of these, 62 were international guidance, 175 na-
tional guidance, and 10 local guidance (e.g. at Trust or
hospital level). Of the national guidance, 87 were devel-
oped in the UK, with Cochrane reviews cited in 30 sets of
NICE guidance and 23 sets of SIGN guidance. Informa-
tion on inclusion in guidelines (by CRG) is summarised in
Table 5.
We interviewed eight participants, four from NICE (or
NICE collaborating centres), two from SIGN and two from
the WHO. Five of the interviewees were female and three
were male. Two participants were senior managers involved
at a strategic level in co-ordinating guideline development,
and six were involved in the production of individual guide-
lines either as managers, systematic reviewers or technical
advisors. More details of the participants and their rolescan be seen in Table 6. Analysis of the interview tran-
scripts resulted in six overarching themes and a number of
subthemes relating to the views and experiences of guide-
line developers and their use of Cochrane reviews. The
overarching themes are the following: the process of
using Cochrane reviews in the development of guidance,
the quality of Cochrane Reviews, culture and approaches,
up-to-date evidence, methodological issues and collabor-
ation and communication. These themes and subthemes
can be seen in Table 7. Whilst a number of the issues that
arose might be applicable to systematic reviews in general,
the focus of our questions and analysis was on the use of
Cochrane reviews.
Results from the semi-structured interviews suggest
that searching for relevant Cochrane reviews is part of
the guideline development process and that Cochrane
reviews often play an instrumental role in informing
guidance. Cochrane reviews appeared to be used at a
number of different stages of the guideline development
process, for example, being used early in the process to
scope review questions and assess the strength of the
evidence and later in the process as part of the evidence
review to develop the guidance. Even when the whole
Cochrane review was not used, guideline developers
often drew on component parts of the review such as
search strategies, lists of included and excluded studies,
quality assessment data and analyses. However, there
were a number of barriers to the use of Cochrane re-
views in guidance. Cochrane reviews might not be avail-
able, they might not fit with the guideline scope, they may
be out of date, or the methods used may not fit with
those required for the guideline (see Table 7). Evidence to
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file 6.
Impact on clinical practice and services
There was evidence to suggest that some Cochrane re-
views may have contributed to a number of benefits to
the health service including safer or more appropriate
use of medication or other health technologies or the
identification of new effective drugs or treatments (see the
list below). Eight CRGs and 12 authors gave examples of
impact on practice or services. However, it was difficult to
verify some of these impacts and to judge whether these
changes were directly attributable to the Cochrane re-
view(s). Eighty-three percent of review authors who
responded to the questionnaire were unsure if their workhad changed the behaviour of practitioners, managers or
members of the public, or if their work had helped reduce
costs (69%), increase quality (76%), improve effectiveness
(76%) or promote equity (79%).
 A review on support surfaces for pressure ulcer
prevention [27] was used to inform guidance on
purchasing within the NHS [28].
 Reviews on long-acting beta-antagonists (LABA)
in asthma [29-31] may have led to safer prescribing
of these drugs for people with asthma (http://www.
fda.gov/Drugs/DrugSafety/PostmarketDrugSafety
InformationforPatientsandProviders/ucm200776.htm).
 A review on colloids versus crystalloids for fluid
resuscitation [32,33] may have influenced calls to
Table 3 Number of citations (WoS, Scopus and Google Scholar) and Altmetric score
CRG Review IDa Year of publication Downloads 2011
(full text)
WoS Scopus GS Altmetric
score
Airways A1 2009 477 35 35 59 6
A2 2009 2,195 49 80 168 6
A3 2011 1,760 4 9 41 0
Bone, Joint and Muscle B1 2007 3,047 66 123 248 8
B2 2009 9,602 348 467 737 77
B3 2010 6,581 96 42 242 39
Cystic Fibrosis C1 2009 939 10 8 25 0
C2 2008 356 4 12 19 0
C3 2007 274 15 18 43 0
Dementia and Cognitive Improvement D1 2008 1,660 37 59 100 1
D2 2009 705 58 104 147 2
D3 2007 2,599 42 104 185 2
Depression, Anxiety and Depression DA1 2007 1,019 8 10 24 0
DA2 2008 5,080 138 235 441 51
DA3 2008 1,134 51 83 276 1
Ear, Nose and Throat ENT1 2008 313 9 11 18 1
ENT2 2007 971 56 103 168 11
ENT3 2007 725 121 260 338 1
Epilepsy E1 2008 147 7 19 32 0
E2 2011 427 1 1 10 2
E3 2008 1,187 17 40 100 0
Eyes and Vision EV1 2007 367 1 11 45 0
EV2 2009 417 0 2 65 0
EV3 2009 704 12 21 34 3
Gynaecological Cancer GC1 2007 364 23 28 64 1
GC2 2011 295 53 21 129 0
GC3 2008 383 28 48 61 0
Heart H1 2008 618 16 47 95 13
H2 2011 10,453 54 65 282 34
H3 2010 2,440 56 75 225 1
Incontinence IN1 2007 215 10 10 15 0
IN2 2011 449 4 2 5 0
IN3 2010 774 6 5 11 0
Injuries IJ1 2008 127 7 11 13 0
IJ2 2007 3,720 86 201 735 106
IJ3 2007 1,373 81 188 595 0
Neuromuscular NM1 2009 222 8 7 9 0
NM2 2008 414 14 29 46 1
NM3 2008 761 57 127 305 0
Oral Health O1 2008 489 2 5 6 0
O2 2007 413 2 15 14 11
O3 2010 1,276 25 15 103 13
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Table 3 Number of citations (WoS, Scopus and Google Scholar) and Altmetric score (Continued)
PaPaS P1 2009 1,589 58 103 151 7
P2 2008 2,238 27 86 139 4
P3 2008 2,200 93 176 276 69
Pregnancy and Childbirth PC1 2008 569 13 27 37 0
PC2 2008 323 11 16 34 0
PC3 2010 3,258 29 16 499 37
Schizophrenia SCH1 2008 222 5 7 20 3
SCH2 2010 1,666 7 16 74 1
SCH3 2008 2,560 30 59 103 2
Skin SK1 2007 624 14 29 67 0
SK2 2009 327 5 10 16 0
SK3 2009 581 16 19 70 0
Tobacco Addiction T1 2008 903 42 89 162 1
T2 2009 762 40 61 126 2
T3 2010 1,481 33 31 123 17
Wounds W1 2008 3,487 12 27 51 0
W2 2011 123 3 0 5 4
W3 2008 1,088 37 43 102 3
aFor each CRG, the first review listed was chosen randomly and the other two were on the basis they may have had an impact.
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the potential to save both lives and money [34].
 An updated review on antiviral treatment for Bell’s
palsy [35] may have contributed to changes in practice
and a reduction of prescriptions of antiviral drugs for
Bells palsy (http://cks.nice.org.uk/bells-palsy).
 A review on antifibrinolytic drugs for trauma
patients [36,37] led to follow-on research which
influenced the decision by the Medicines Innovation
Scheme to fast track tranexamic acid for use in the
NHS. Ambulance crews throughout the NHS now
administer tranexamic acid to bleeding trauma
patients (http://www.swast.nhs.uk/txa.htm).
Potential benefits of Cochrane reviews were highlighted
in the NICE Cochrane Quality and productivity topics, 19
of which related to reviews produced by one of the 20
CRGs during the years 2007–2011. Potential benefitsTable 4 Summary of citation analysis data from WoS,
Scopus and Google Scholar
WoS Scopus Google
scholar
Total number of citations
(all 60 reviews combined)
2,192 3,562 8,333
Mean number of citations 36.5 59.3 138.8
Median number of citations 20 28.5 72
Interquartile range 7–51 11–80 25–168
Variation in counts 0–348 0–467 5–737identified included economic benefits through budget
savings or the release of funds, improvements in clinical
quality, the reduction in the use of unproven or unneces-
sary procedures and improvements in patient and carer
experiences.
Discussion
Summary of findings
There was evidence that reviews from all the CRGs had
had some impact. The clearest impacts were on health-
care policy, with less evidence of direct impact on re-
search targeting, clinical practice and the organisation
and delivery of NHS services. From our sample of 60
reviews, there was evidence to suggest that some reviews
have had a significant impact on the research and prac-
tice communities, whilst others appear to have had little
or no impact (a summary of the main impacts of the 60
reviews can be seen in Additional file 7). Some of the re-
views associated with the clearest evidence of impact
had been updated during 2007–2011 rather than first
published during that time [33,38,39].
There was considerable variation in evidence of impact
between CRGs and between reviews. Variation between
CRGs might be accounted for by differences in the scope
or speciality of the group, the type and number of out-
puts, or methods used for dissemination and knowledge
transfer. However, it may also be a reflection of whether
CRGs routinely collect data on impact. Variation amongst
the sample of 60 reviews might be a reflection of the rele-
vance of the review findings to decision makers, the date of
Table 5 Summary of information relating to inclusion of reviews in guidelines (stratified by CRG)
CRG Total number
of citations
Number of reviews cited
in guidelines/guidance
Total number
of guidelines
Level of guideline
International National Local
Airways 54 45 16 3 13 0
BJM 18 12 9 0 8 1
Cystic Fibrosis 16 15 13 3 9 1
DAN 84 52 26 10 16 0
Dementia and Cognitive Improvement 14 14 5 1 4 0
ENT 33 21 17 3 14 0
Epilepsy 8 7 3 1 2 0
Eyes and Vision 8 6 6 0 3 3
Gynaecological Cancer 7 7 3 0 3 0
Heart 37 19 26 5 21 0
Incontinence 29 22 9 1 8 0
Injuries 42 29 18 8 10 0
Neuromuscular 8 6 7 5 2 0
Oral Health 47 17 25 1 20 4
PaPaS 48 33 20 4 15 1
Pregnancy and Childbirth 129 85 33 15 18 0
Schizophrenia 57 43 8 8 6 0
Skin 20 14 14 3 11 0
Tobacco Addiction 22 18 7 0 7 0
Wounds 41 25 11 1 10 0
Bunn et al. Systematic Reviews 2014, 3:125 Page 10 of 15
http://www.systematicreviewsjournal.com/content/3/1/125publication, the strength of the evidence or the strategies
used to disseminate the findings.
Knowledge production and research targeting
We found evidence to suggest that some Cochrane re-
views had played a role in identifying gaps in the evidence
and stimulating new research. Across the CRGs, there
were 40 examples of reviews influencing primary research.
However, most of these examples of research impact related
to work conducted by the Cochrane reviewers themselves;
there was less evidence of a broad impact on stimulating
new research.
Based on the assumption that influential or important
work will be cited more frequently than others [40] andTable 6 Details of interview participants
Organisation Number of
participants
Role
NICE - internal 2 Technical analyst, clinical
guidelines team × 2
NICE - external collaborating
centres
2 Senior systematic
reviewer × 2
SIGN 2 Evidence and information
scientist × 1
Programme manager × 1
WHO 2 Senior manager × 2that alternative metrics give an indication that papers have
been read and discussed [26], the results of the bibliomet-
ric analysis suggest that a number of the reviews had had
an impact on the creation of new knowledge and the
stimulation of discussion and debate. Citation counts were
much higher in Google Scholar than in WoS or Scopus.
Google Scholar may be of particular importance to cit-
ation analyses for Cochrane reviews as previous work
[41,42] suggests that citation counts for Cochrane reviews
are artificially low in ISI databases and Scopus because cit-
ing authors have incorrectly referenced Cochrane reviews.
However, as there are also some concerns about the
accuracy of Google Scholar [43], evaluations of citation
data for Cochrane reviews should include more than one
database.
Informing policy development
Reviews from all the CRGs were cited in some form of
clinical or practice guidance. Mostly, this was national
and international guidance, with only ten examples of
local guidance. This may be because local guidance is
often not available outside of the organisations involved
and so may be more difficult to find. CRGs and review
authors gave us a number of anecdotal examples of
reviews influencing local guidance (for example, at hos-
pital or department levels), but most were excluded from
Table 7 Results of thematic analysis and barriers and facilitators to the use of Cochrane reviews in the development of
guidance
Themes and subthemes Barriers and facilitators
Theme 1. The process of using Cochrane reviews (CRs) in the
development of guidance
• CRs used early in process/used in development phase Barriers
• Systematic reviews top of evidence hierarchy/priority over
other forms of evidence
• CRs may not be available, may not fit with guideline scope
• Guideline developers (GD) will use CR if available, but not
always possible—CR may not be available/may not ‘fit’
• CR may be out of date
• GD may use whole CR or parts of CR (e.g. using evidence tables)/
parts used vary
Facilitators
• CRs can save GD time (e.g. using existing searches/data) • Similar evidence hierarchy
• GD may build on work of Cochrane reviewers/existing reviews • Cochrane processes for searching/ identifying studies
seen as reliable and thorough
• GD may redo the review (depending on resources) • Similar processes for critical appraisal
• Structure of CR means that GD can use all or part of it
Theme 2. Quality of Cochrane reviews
• Cochrane is a respected/trustworthy brand Barriers
• Transparent/easy to replicate • Quality not always good
• Robust methods • Quality may be poorer in older reviews
• Variable quality (not all good) Facilitators
• Perception that quality may be poorer in older reviews • Generally respected/trustworthy brand
• Robust methods that can be replicated
Theme 3. Culture and approaches
• Cochrane and GD have similar attitudes towards evaluating
and appraising evidence
Barriers
• Cochrane reviews routinely used to inform guideline development
process
• Different time frames and resources
• Some differences in methods (e.g. CR double data extraction but
some GD not)
• Different priorities of Cochrane and GD
• Role of judgement (part of guideline development process but not CR) • Different needs and perspectives
• Cochrane and GDs may have different scopes/focus/drivers
behind review questions
Facilitators
• Tensions between different perspectives and interests
(e.g. academic/clinical/policy)
• Similar attitudes towards evaluating and synthesising evidence
• Resources—different time frames and sources of funding • Cochrane embedded in culture of guidelines
Theme 4. Up-to-date evidence
• CRs can be out of date (become out of data quickly) Barriers
• Some confusion around dates of updates • Cochrane too slow to update
• Some GD (e.g. WHO) work with CRGs to update reviews
(they fund this)
• Lack of resources to fund reviews/updates
• Delay in publication/updating • Slow editorial processes
Facilitators
• Guideline developers fund CRG to update review
Theme 5. Methodological issues
• Newer is better (newer CRs seen as methodologically better) Barriers
• May be statistical issues (wrong data/statistical methods—
barrier to use)
• Statistical issues (e.g. CR not used outcome measures,
statistics GD want)
• Lack of clarity on which follow-up data used from papers • Need for network meta-analysis and comparative analysis reviews
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Table 7 Results of thematic analysis and barriers and facilitators to the use of Cochrane reviews in the development of
guidance (Continued)
• Network meta-analysis, comparative analysis reviews • Lack of facilities for sharing data
• GRADE (NICE have to use it, Cochrane do not)
• Cochrane focus on RCTs—not always appropriate, particularly
for public health
• GD want better facilities for sharing and reanalysing data
from CRs
Theme 6. Collaboration/communication
• Good communication improves use of review Barriers
• Timing of communication is important • Problems communicating with review authors and CRGs
• Dialogue/clear communication/negotiation important with appropriate
persons
• Issues of ownership and authorship
• Collaboration and positive engagement might help speed
things up
Facilitators
• Close collaboration between WHO and certain Cochrane groups • Good communication between GD and authors or CRGs improves
use of CR (timing important)
• Formal links between CRG and guideline developers to
promote use of CR
• Financial support
• GD experience problems communicating with CRGs
• Issues of ownership/authorship—recognition and reward
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the guidance in order to verify that it referenced a
Cochrane review. It is possible, therefore, that the impact
of Cochrane reviews on local guidance is underestimated
in our evaluation.
The fact that a review is cited in a guideline does not
mean that it was instrumental in the development of the
final guidance. Conversely, a Cochrane review might have
been used to inform policy development but may not be
referenced or cited. Interviews with guideline devel-
opers suggest that Cochrane reviews are routinely used to
inform the guideline development process. However,
reviews with a narrow focus or that are out of date are of
less use to decision maker.
Impact on clinical practice and services
Review authors who responded to the questionnaire were
generally unsure if their work had changed the behaviour
of practitioners, managers or members of the public, or if
their work had helped reduce costs, increase quality,
improve effectiveness or promote equity. CRGs and
authors did provide some examples to suggest that
Cochrane reviews had contributed to a number of benefits
to the health service including safer or more appropriate
use of medication or other health technologies or the iden-
tification of new effective drugs or treatments, or that
they had the potential to lead to cost-saving and
health-service benefits. However, attributing particular
behaviour changes, health benefits or cost saving to aparticular systematic review (or reviews) is difficult.
Generally, new research adds to an existing pool of
knowledge [44] and many research projects may lie
behind a specific advance in health care [45]. Many
Cochrane reviews have a narrow focus, often deliberately.
Whilst, this may ensure internal validity, it may reduce its
impact in the policy and practice arenas, a factor recognised
in the move by the Cochrane Collaboration to introduce
overviews of reviews [46].
Strengths and limitations
Evaluating the impact of research is complicated. At
present, there are no agreed instruments or methods for
determining impact [47], and it is acknowledged that
knowledge production is more easily discernible than im-
pact on policy or health gain [21]. Moreover, although
health benefits and broader economic benefits may be
viewed as the real ‘payback’ from health research, these
are hard to measure as it is difficult to attribute particular
health gains to specific pieces of research [23]. Although
we were able to make some inferences about health and
economic benefits, these were largely beyond the remit of
this study.
Our approach included the use of citation analysis and
documentary review. Bibliometric techniques have been
criticised for focusing on quantity rather than quality,
and measuring the number of research outputs rather
than research outcomes or impact [20]. Moreover, it
may take several months or even years for a work to be
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counts with the use of alternative metrics. This gave us
another measure of the amount of attention a review
had received including its impact in social media. In
addition, our mixed methods approach, including docu-
mentary review, questionnaires with CRGs and review
authors, and interviews with guideline developers, en-
abled us to get a more complete picture of impact.
We interviewed only eight guideline developers, six of
whom were based in the UK, and all of whom came from
leading guideline development agencies. It is possible that
their views and experiences may not be directly transfer-
able to other organisations or to guideline developers in
other countries. However, we found consistent and recur-
ring themes in the interviews, and the views expressed are
concordant with literature in this area [48,49].
We examined the impact of three reviews per CRG.
Our sample is relatively small, and it is possible that the
reviews we chose are not typical of the outputs of those
CRGs, that there are better examples of impact and that
the findings are not generalizable. Moreover, only 48% of
the authors responded to the survey which raises further
questions about the generalizability of the findings.
However, this response rate compares favourably with
previous surveys of Cochrane authors [50].
Although most of the data in the report are presented
stratified by CRG, direct comparisons between reviews or
between CRGs may not be appropriate. The diverse nature
of the review topics and the differences in the number of
questionnaires returned for each group and in length of
time since publication mean that one should be cautious
when comparing the impact of different reviews. Citation
volume typically peaks in the third or fourth year post-
publication, and therefore, a window of 5 years has been
suggested as most appropriate for research assessment
[51,52]. Reviews published more recently may not yet have
had time to impact on policy or practice. Indeed, it has
been suggested that it may take up to a decade for the full
impact of research to be apparent [53].
There are several potential sources of bias in this evalu-
ation. This was a retrospective analysis and as such may
be at greater risk of bias than one where data is collected
prospectively. In addition, much of our data was obtained
from questionnaires to CRGs and review authors, and
there is a risk of recall bias or that respondents might have
inflated the impact of their work. In order to overcome
this, the research team critically assessed all information
provided and sought evidence to verify impacts and check
whether it was related to an output produced in the time
frame of interest.
Implications of the findings
Our study provides evidence that Cochrane reviews pro-
duced by NIHR-funded CRGs have an impact on clinicalguidance development and may have influenced the con-
duct of primary research. We found limited evidence
that Cochrane reviews had had a direct effect on clinical
practice, but they may have an indirect impact on health
care and patient outcomes through their role in informing
further primary research and clinical guidance. Although
the implementation of NICE guidance has been shown to
be variable [54,55], there is evidence that clinical guide-
lines can be effective in changing the process and outcome
of care [56-60].
There are significant difficulties associated with deter-
mining the impact of specific pieces of research [21]. The
focus of this evaluation was on the outputs of 20 CRGs
covering a broad range of health-care topics. It is possible
that it would be easier to determine impact on clinical
practice and the behaviour of health-care providers if such
evaluations had a narrower focus. This might allow the
use of more qualitative and quantitative methods targeted
at specific groups of health-care providers.
Interviews with guideline developers suggest that
Cochrane reviews are routinely used in the guideline de-
velopment process. However, reviews with a narrow
focus or that are out of date are of less use to decision
makers. Use of Cochrane reviews in the development of
guidelines might be facilitated by better collaboration and
communication between CRGs and guideline developers.
Formal as well as informal networks might be needed to
facilitate the transfer of research knowledge to decision
makers [61].
Conclusions
This study identified a number of impacts and likely
impacts of Cochrane reviews. The clearest impacts of
Cochrane reviews were on health-care policy, with less evi-
dence of a direct impact on clinical practice and the organ-
isation and delivery of NHS services. Whilst it is important
for researchers to consider how they might increase the in-
fluence of their work, such impacts are difficult to measure.
Questions remain about how we define and measure im-
pact, and more work is needed to develop suitable methods
for evaluating the impact of systematic reviews.Additional files
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